BRAF and melanoma: Later on, several groups, working on different BRAFV600E-expressing melanoma xenograft models, reported the striking efficacy of another BRAF inhibitor, PLX4032 (now Vemurafenib), in inducing a partial or complete tumor regression and prolonged animal survival, in a dose-dependent manner and without signs of toxicity [25,26,27].